FDA Called Two Sentences on a Ketamine Booth Extremely Concerning
The FDA told a drug developer that two sentences on a conference booth were extremely concerning. The product is an extended release ketamine injection. The venue was the American Psychiatric Association annual meeting. FiercePharma reported the action, and the language the agency objected to is language a lot of ketamine marketing borrows.
Marketing review is cheaper than the letter that follows a bad claim. HealingMaps’ GPO, the first built for the ketamine industry, gets member clinics 40 percent or more off medical supplies, 15 to 20 percent off malpractice and liability premiums, discounted LegitScript certification, and 20 to 30 percent off HIPAA compliant payment processing. Joining is free with no obligation. See what your clinic qualifies for →
| Key Takeaway | Detail |
|---|---|
| What happened | FDA’s Office of Prescription Drug Promotion issued an untitled letter on August 21, 2026 |
| Who received it | Alar Pharmaceuticals, over ALA-3000, an investigational extended release ketamine for treatment-resistant depression |
| Where | An exhibit booth and brochure at the American Psychiatric Association 2026 Annual Meeting |
| The flagged claims | “Breaks Key Barriers in Ketamine Therapy” and “No overall sedative, dissociative, psychosis-like side effects” |
| The other problem | The booth never disclosed that ALA-3000 is investigational and not approved for sale |
| Why it is unusual | OPDP’s first untitled letter on preapproval promotion since 2019 |
What Alar Was Promoting
ALA-3000, also identified as ketamine pamoate, is an extended release injectable ketamine. It is in development for treatment-resistant depression. It is investigational, and not approved for commercial distribution in the United States.
The company took an exhibit booth at the APA annual meeting and handed out a brochure. Both promoted the product as safe and effective for treatment-resistant depression.
That is the core violation. A company may discuss an investigational product in scientific contexts. It may not promote one as safe and effective before approval.
The Two Claims FDA Singled Out
The first was a headline: ALA-3000 breaks key barriers in ketamine therapy for treatment-resistant depression.
The second was a bulleted safety claim. No overall sedative, dissociative, psychosis-like side effects.
OPDP called those claims extremely concerning given the apparent absence of adequate data to support them. It also flagged the implication that the product is different from or better than approved treatments.
The Missing Disclosure Mattered Too
The letter did not stop at the claims. OPDP noted the booth carried nothing indicating ALA-3000 is an investigational drug that has not been approved.
It also observed that the booth sat in the exhibit hall near booths for approved products. Context was part of the problem. A psychiatrist walking that aisle had no signal separating an approved therapy from one still in development.
That is a useful reminder that placement and framing count, not just sentences.
This Is Rarer Than It Looks
Untitled letters about preapproval promotion are not routine. This is OPDP’s first one of that type since a November 2019 letter to Nascent Biotech.
It is also the office’s first preapproval promotion enforcement action of any kind since a warning letter in February 2022.
So this is not a form letter. The agency chose to act after roughly seven years of silence on this violation. It chose a ketamine product to do it with.
An Untitled Letter Is Not a Warning Letter
The distinction matters and most coverage blurs it. An untitled letter is the lower tier of FDA enforcement correspondence.
It identifies violations and asks the company to respond and correct. A warning letter carries a stronger statement of consequences and a formal compliance posture behind it.
Anyone describing this as a warning letter is reporting it wrong. Alar was cited, not sanctioned.
What Transfers to Clinics, and What Does Not
The regulatory posture does not transfer. OPDP regulates prescription drug promotion by manufacturers, not the practice of medicine. A clinic advertising off-label ketamine will not receive this letter.
The claims transfer completely. No clinic can support a blanket promise that its ketamine protocol produces no dissociative effects. That is not true of ketamine at therapeutic doses.
And clinic advertising is not unregulated. State medical boards reach it, and so does the FTC, as clinics saw when it sued Hims and Hers over tracking pixels.
The Phrases Worth Auditing
Three categories drew the letter, and all three appear in clinic copy. Absence claims that promise no dissociation, no sedation or no side effects. Superiority claims that position a treatment as better or safer than approved alternatives.
And barrier-breaking language, which sounds like marketing but reads as an efficacy claim to a regulator.
We spot checked 100 ketamine clinic listings in our directory, reading each homepage and one services page. The absence language barely appeared in ketamine copy. Where it did show up, it was nearly always describing TMS, which genuinely does not require sedation.
The Bottom Line
The industry mostly is not making these claims. That is worth knowing, and it is the opposite of the story most enforcement coverage tells.
The narrow lesson is for anyone writing copy about an unapproved product, or about effects nobody has measured. FDA just showed it will act on both after years of not doing so. Our guide to the FDA psychedelic rulebook covers the wider compliance picture. The IV ketamine approval pathway explains what an approved indication would change.
Patients looking for supervised care can start with our directory of verified ketamine clinics.
This article is for informational purposes and is not legal or medical advice. Clinics with questions about advertising compliance should consult qualified counsel.
